139 related articles for article (PubMed ID: 1492223)
21. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
22. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
Hainsworth JD; Wright EP; Gray GF; Greco FA
J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
[TBL] [Abstract][Full Text] [Related]
23. Carcinoma of unknown primary site.
Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
[TBL] [Abstract][Full Text] [Related]
24. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
26. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.
Gill I; Guaglianone P; Grunberg SM; Scholz M; Muggia FM
Anticancer Res; 1991; 11(3):1231-5. PubMed ID: 1888154
[TBL] [Abstract][Full Text] [Related]
27. Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections.
Liu JM; Chen YM; Chao Y; Liu SM; Tiu CM; Wu HW; Chiou TC; Hsieh RK; Chen LT; Whang-Peng J
Jpn J Clin Oncol; 1998 Jul; 28(7):431-5. PubMed ID: 9739784
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Balaña C; Manzano JL; Moreno I; Cirauqui B; Abad A; Font A; Mate JL; Rosell R
Ann Oncol; 2003 Sep; 14(9):1425-9. PubMed ID: 12954583
[TBL] [Abstract][Full Text] [Related]
29. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.
Pavlidis N; Kosmidis P; Skarlos D; Briassoulis E; Beer M; Theoharis D; Bafaloukos D; Maraveyas A; Fountzilas G
Ann Oncol; 1992 Sep; 3(8):631-4. PubMed ID: 1450045
[TBL] [Abstract][Full Text] [Related]
30. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)].
Okano M; Oda H; Ishihara M; Tamaru S; Saito K; Yamashita Y; Mizuno T; Katayama N
Gan To Kagaku Ryoho; 2018 Apr; 45(4):643-645. PubMed ID: 29650822
[TBL] [Abstract][Full Text] [Related]
32. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy.
Carlson RW; Dorfman RF; Sikic BI
Cancer; 1990 Nov; 66(10):2092-4. PubMed ID: 1699650
[TBL] [Abstract][Full Text] [Related]
34. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
Milliken ST; Tattersall MH; Woods RL; Coates AS; Levi JA; Fox RM; Raghavan D
Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1645-8. PubMed ID: 2448145
[TBL] [Abstract][Full Text] [Related]
35. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
[TBL] [Abstract][Full Text] [Related]
36. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
37. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin and etoposide in advanced colorectal carcinoma.
Passalacqua R; Bisagni G; Cocconi G; Boni C; Di Blasio B; Ceci G
Ann Oncol; 1991 Oct; 2(9):687-8. PubMed ID: 1742225
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.
Lluch A; Azagra P; Cervantes A; Muñoz M; Alberola V; Santabarbara P; García-Conde J
Oncology; 1994; 51(4):352-5. PubMed ID: 8208520
[TBL] [Abstract][Full Text] [Related]
40. Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
Culine S; Fabbro M; Ychou M; Romieu G; Cupissol D; Pinguet F
Cancer; 2002 Feb; 94(3):840-6. PubMed ID: 11857320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
